Rethinking gene therapy development strategy: Shifting from technological acceleration to mechanism-based safety governance
-
-
REFERENCES
[1] Huang Y., Wang Z., Zhong C., et al. (2024). CRISPRa engineered Elite macrophages enable adoptive cell therapy for rheumatoid arthritis. Innov. Med. 2:100050. DOI:10.59717/j.xinn-med.2024.100050 [2] Zhang J., Xiang W. and Ma D. (2025). Individualized gene editing: A leap forward in treating rare genetic disorders. The Innovation 6:101116. DOI:10.1016/j.xinn.2025.101116 [3] The Innovation Medicine News Team. (2026). Itvisma expands the frontiers of gene replacement therapy for spinal muscular atrophy. Innov. Med. 4:100243. DOI:10.59717/j.xinn-med.2026.100243 [4] Borrell B. (2026). Death of girl in Chinese gene-editing trial was never made public. Science 393:347-353. https://www.science.org/content/article/exclusive-death-girl-chinese-gene-editing-trial-was-never-made-public. [5] Ledford H. (2025). The baby whose life was saved by the first personalized CRISPR therapy. Nature 648:528−529. DOI:10.1038/d41586-025-03847-2 -
ABOUT THIS ARTICLE
Cite this article:
The Innovation Medicine Editorial Team. (2026). Rethinking gene therapy development strategy: Shifting from technological acceleration to mechanism-based safety governance. The Innovation Medicine 4:100256. https://doi.org/10.59717/j.xinn-med.2026.100256
Welcome!
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Export File
Citation
The Innovation Medicine Editorial Team. (2026). Rethinking gene therapy development strategy: Shifting from technological acceleration to mechanism-based safety governance. The Innovation Medicine 4:100256. https://doi.org/10.59717/j.xinn-med.2026.100256
Format
Content
DownLoad:
-
Figure 1.
Gene therapy development must move from first-in-human acceleration toward mechanism-based safety governance.
